Earnings call
Acutaas Chemicals Q1 FY26 earnings call: The full benefit of Acutaas Chemicals Limited's solar power plant will be visible from Q3 FY '26 onwards
By DalalOS Data Desk. Assembled by software from the company's transcript. Not reviewed by a person.
Transcript filed .
The full benefit of Acutaas Chemicals Limited's solar power plant will be visible from Q3 FY '26 onwards. The company completed its Ankleshwar capex, with the last pending block commercialized in Q1 FY '26. The company revenue for Q1 FY '26 grew by 17.3% year-on-year to INR2,072 million, primarily from its advanced pharmaceutical intermediates business, while its specialty chemicals business was steady. The company has a very good pipeline with the originator business, which it has structured over more than 15 years. A long-term supply contract is in place for the Fermion product with patent expiry beyond 2033 and patent expiry in most geographies in 2035, providing visibility.
The numbers management gave
Results
- The company revenue for Q1 FY '26 grew by 17.3% year-on-year to INR2,072 million, primarily from its advanced pharmaceutical intermediates business, while its specialty chemicals business was steady.
Show source
Our revenue for Q1 FY '26 grew by 17.3% year-on-year to INR2,072 million.
- Pharmaceutical intermediates segment delivered revenue of INR165.8 crores in Q1 FY '26, up 23.3% Y-o-Y, driven by its core advanced pharmaceutical intermediates business and the CDMO segment.
Show source
This segment delivered revenue of INR165.8 crores in Q1 FY '26, which is strong growth of 23.3% Y-o-Y, which was driven by core advanced pharmaceutical intermediates business as well as the CDMO segment.
- Specialty chemicals business segment reported flattish revenue of INR41.4 crores in Q1 FY '26.
Show source
This business segment reported flattish revenue of INR41.4 crores during the quarter.
- Commodity chemicals business saw healthy growth driven by volumes and steady pricing, offset by softer performance of Baba Fine Chemicals business, in Q1 FY '26.
Show source
While the commodity chemicals business saw healthy growth Page 3 of 16 Acutaas Chemicals Limited July 30, 2025 driven by volumes and steady pricing, this was offset by softer performance of Baba Fine Chemicals business.
- Capital expenditure for Q1 FY '26 stood at INR69 crores, primarily allocated to the electrolyte additive project at its Jhagadia site.
Show source
On the capital expenditure side, capex for the quarter stood at INR69 crores, primarily allocated to Jhagadia site for electrolyte additive project.
- Revenue from operations for Q1 FY '26 reached INR207 crores, representing 17.3% growth Y-o-Y; gross profit was INR110.3 crores, up 48.4% compared to the same period last year.
Show source
Revenue from operations for the quarter reached INR207 crores, representing 17.3% growth Y-o-Y. Gross profit for the quarter was INR110.3 crores, reflecting 48.4% increase compared to the same period last year.
Show 11 more statements
Results
- Gross margin in Q1 FY '26 expanded by 1,117 basis points Y-o-Y to 53.2%.
Show source
The gross margin expanded by 1,117 basis points Y-o-Y to 53.2%.
- Gross margin in Q1 FY '26 was driven by cost optimization initiatives and improved product mix.
Show source
Gross margin was driven by cost optimization initiatives as well as improved product mix.
- EBITDA for Q1 FY '26 was INR50.9 crores, up 72.4% Y-o-Y, and its EBITDA margin was 24.6%, up 785 basis points Y-o-Y, driven by expansion in gross margin.
Show source
EBITDA for the quarter was INR50.9 crores, which was up 72.4% Y-o-Y. EBITDA margins were at 24.6%, up 785 basis points Y-o-Y. EBITDA margin was driven by expansion in gross margin.
- PAT for Q1 FY '26 was INR44 crores, three times its PAT of INR14.7 crores in Q1 FY '25, driven by higher EBITDA margin and strong other income from foreign currency gains.
Show source
PAT for the quarter was INR44 crores, which grew 3x compared to the PAT of INR14.7 crores in Q1 FY '25.
- PAT margin for Q1 FY '26 was 21.2%, an expansion of 1,292 basis points Y-o-Y.
Show source
PAT margin for the quarter was 21.2%, which show an expansion of 1,292 basis points Y-o-Y. Moving on to the balance sheet item.
- Net cash and cash equivalents were INR270 crores in Q1 FY '26.
Show source
Net cash and cash equivalents were at INR270 crores.
- Working capital was around 128 days in Q1 FY '26, an increase of 14 days compared to Q4FY '25, mainly due to lower payable days from advance payment for better raw-material pricing; for the full year, Acutaas Chemicals Limited believes working capital would be around 110 days.
Show source
Our working capital for the quarter was around 128 days, which was increased by 14 days compared to Q4FY '25.
- Acutaas Chemicals' Pharma segment margin is around 28% and its specialty segment margin is around 11% in Q1 FY '26.
Show source
Bhavin Shah: So segmental margin for Pharma is around 28% and specialty is around 11%.
- The company had other income of INR16 crores, including around INR12.5 crores of foreign exchange gain and INR3.5 crores of interest income in Q1 FY '26.
Show source
Bhavin Shah: So, in this quarter, we have other income of INR16 crores.
- Working capital increase in Q1 FY '26 was mainly due to lower payable days from advance payment for better raw-material pricing; for the full year, Acutaas Chemicals Limited believes working capital would be around 110 days. Replaced by a later filing.
Money and capital
- The company expects its capex for the current year to be around INR250 crores and has sufficient cash on hand to fund it.
Show source
Overall, the capex for the current year is expected to be around INR250 crores, and we have sufficient cash on hand to fund this capex.
What it expects ahead
What management expects
- The full benefit of Acutaas Chemicals Limited's solar power plant will be visible from Q3 FY '26 onwards.
Show source
Full benefit of this solar power plant will be visible from Q3 FY '26 onwards.
- Remaining CDMO projects are progressing as planned and are expected to begin contributing to the top line from Q4 FY '26 onwards.
Show source
On the business update, starting with Pharmaceutical Intermediates segment, our remaining CDMO projects are progressing as per plan and are expected to begin contribution to the top line from Q4 FY '26 onwards.
- The company expects developments in its battery chemicals business to translate into commercial contracts starting FY '27.
Show source
However, we expect these developments to translate into commercial contracts starting FY '27.
- The company reaffirmed confidence in delivering 25% revenue growth in FY '26; Acutaas Chemicals Limited maintains its guidance of 25% for FY26.
Show source
Before I conclude, I want to reaffirm our confidence in delivering 25% revenue growth in FY '26.
- The company expects 1.5x asset turn in the business.
Show source
But what we can say is we are expecting 1.5x the asset turn in this business.
- The company says its planned capacity of 2,000 metric ton of VC and 2,000 metric ton of FEC has full visibility and will ramp up very fast in FY '27.
Show source
But just let me give you the update that we now have a full visibility on the capex we have planned for 2,000 metric ton of VC and 2,000 metric ton of FEC so it will ramp up very fast in FY '27.
Show 13 more statements
What management expects
- The company has a strong product and R&D pipeline for its ex CDMO business up to API patent expiry beyond 2040; intermediates have been developed, sampled and submitted to the customer on a commercial scale, providing visibility and confidence that the ex CDMO intermediate business will keep growing.
Show source
Abhishek Patel: For the ex CDMO business we have good visibility in terms of our product pipeline as we have very strong product pipeline, R&D pipeline up to patent expiry of API beyond 2040.
- The company estimates that production in its semiconductor materials area will start early 2027.
Show source
And this will start early 2027, that is the estimate right now, production and everything, as you mentioned earlier.
- Three additional CDMO projects are expected to be commercialized by end of this financial year; one product from a new project received validation quantity supply in Q4 FY '25 and is expected to begin generating revenue by H2 FY '26 after regulatory approvals.
Show source
But then we have 3 more projects which are expected to get commercialized by end of this financial year and one of that, one of those new projects for one product, we have already supplied the validation quantity in Q4 FY '25.So now after regulatory approvals and all those things in place, it will start giving us the revenue by H2 FY '26.
- The company sees steady-state gross margin for its Specialty Chemicals business in the range of 48% to 50%.
Show source
On steady-state side, I'm seeing the gross margin in the range of 48% to 50% around.
- The company sees revenue potential of INR50 crores to INR100 crores each for the products discussed.
Show source
These are not kind of those blockbuster products in the market, but they are, we see the revenue potential of INR50 crores to INR100 crores each for those products.
- The company anticipates 25% revenue growth in FY26, driven by growth across all business segments. Acutaas Chemicals Limited expects to deliver 25% growth with improved margins in FY26.
Show source
Therefore, I'm confident we shall deliver 25% growth with stronger margin this year.
- The company has good visibility on the product mix and customer base for its Indichem joint venture, and expects business from the venture once the plant is up and running.
Show source
While I can't share customer names but would like to highlight that we already have good visibility on who our customers will be and what kind of business we are expecting from this venture once the plant is up and running.
- The company expects customer developments for new products in the segment to start generating revenue early next financial year, but not in this financial year.
Show source
And from that segment also, the customer developments are already being done and now we are at a good stage to get the revenue, but not in this financial year, it will start from next, early next financial year.
- The company expects other CDMO business to come in this financial year and next year.
Show source
And apart from that, we have other CDMO business also coming in this financial year and next year as well.
- Specialty business has double digit EBITDA margins and is expected to remain in the same kind of territory.
Show source
Abhishek Patel: Specialty business as of now, it is double digit at EBITDA level.
- The company expects its electrolyte additive business to have a better margin profile than its overall spec chem business once the electrolyte additive business picks up.
Show source
Once the electrolyte additive business picks up, it will have a better margin profile than the overall spec chem business.
- The company expects Baba Fine Chem business to have revenue similar to last year's revenue.
Show source
Abhishek Patel: So Baba Fine Chem business side, we are expecting kind of similar revenue as compared to last year revenue.
- The company maintains its guidance of 25% for FY26. Replaced by a later filing.
What it is building and selling
Projects and capacity
- The company completed its Ankleshwar capex, with the last pending block commercialized in Q1 FY '26.
Show source
Last pending block has been commercialized in the current quarter.
- Electrolyte additive capex at its Jhagadia site is on track and expected to be completed by Q3 FY '26.
Show source
Electrolyte additive capex at our site in Jhagadia is on track and expected to be completed by Q3 FY '26.
- The company successfully commissioned its remaining 5-megawatt solar plant, in addition to the 10.8-megawatt plant commissioned last quarter.
Show source
Coming to solar, in addition to 10.8-megawatt plant, which was commissioned last quarter, I am delighted to share the successful commissioning of remaining 5-megawatt solar plant.
- The company has a total 15.8-megawatt power plant that will offset the majority of its electricity cost at its Sachin, Ankleshwar and Jhagadia unit.
Show source
Now we have in total 15.8-megawatt power plant, which will offset majority of our electricity cost at our Sachin, Ankleshwar and Jhagadia unit.
- The company expects capex for the Indichem plant to be completed in the second half of the calendar year 2026, with commercial production beginning by late 2026 or early 2027.
Show source
We expect capex to be completed in second half of the calendar year 2026 with commercial production beginning by late 2026 or early 2027.
- The company has announced INR177 crores of capital expenditure for 2,000 metric ton of VC and 2,000 metric ton of FEC.
Show source
We have announced the capital expenditure of INR177 crores for this business, which is for 2,000 metric ton of VC and 2,000 metric ton of FEC.
Show 10 more statements
Projects and capacity
- The company expects additional infrastructure, utility and other capex of around INR40 crores to INR50 crores in total for the new products.
Show source
And of course, there will be some additional capex would be required in terms of additional infrastructure utility as well as some additional capex, which will be around INR40 crores to INR50 crores in total.
- Acutaas Chemicals' electrolyte additives capex is INR180 crores, pilot plant capex is INR30 crores and maintenance capex is INR40 crores; the electrolyte additives capex includes some infrastructure requirements for a new product.
Show source
The electrolyte additives capex is INR180 crores; pilot plant is INR30 crores and maintenance capex is INR40 crores.
- The company has started capex for a pilot plant at its Sachin unit and hopes to complete it within a year.
Show source
Capex for pilot plant has already started at our Sachin unit.
- The company has finalized the capital expenditure plan and location of the Indichem plant and is moving towards execution.
Show source
The capital expenditure plan and location of the plant have already been finalized, and we're now moving swiftly towards execution.
- The company plans to set up or find new capacity to cater to the demand traction it sees in the market. Replaced by a later filing.
Show source
And in fact, now the next step will be for us to set up or find a new capacity to cater the demand traction what we see in the market.
Segments
- The company has a very good pipeline with the originator business, which it has structured over more than 15 years.
Show source
And apart from that, we have a very good pipeline with the originator business also.
- The company successfully completed a virtual audit of Unit II at Ankleshwar by Japan's PMDA, and Unit II was declared GMP compliant.
Show source
And I'm happy to share that it has been declared GMP compliant.
- The company introduced a couple of new products in its battery chemicals business with both existing and new customers.
Show source
In our battery chemicals business, I'm happy to report that we have introduced a couple of new products with both existing and the new customers.
Deals and partners
- A long-term supply contract is in place for the Fermion product with patent expiry beyond 2033 and patent expiry in most geographies in 2035, providing visibility.
Show source
And there, we have for that particular contract, we have long-term contract already been signed for the product which has got patent expiry beyond 2033 and most of the geography 2035, long- Page 10 of 16 Acutaas Chemicals Limited July 30, 2025 term supply contract is already in place.
- The company is in the final stage of discussion with a large multinational customer in Japan.
Show source
While we have already, we are already well advanced in customer engagement in Korea, I am pleased to share that in Japan, we are in final stage of discussion with a large multinational customer.
Everything else said on the call
Group structure
- The company entered into a joint venture in South Korea named Indichem, where it is investing approximately KRW30 billion; Acutaas Chemicals Limited will hold a 75% stake, and its Korean partner will hold a 25% stake in exchange for technology and market access, and the facility will manufacture specialty chemicals used in chip production.
Show source
We have entered into a joint venture in South Korea named Indichem, where we are investing approximately KRW30 billion.
- The company is investing around KRW 30 billion in its joint venture named Indichem in Korea and will hold a 75% stake; its Korean partner receives the remaining 25% stake for bringing product, technology and market access.
Show source
As Naresh Bhai mentioned, we are investing around KRW 30 billion in Korea in a joint venture named Indichem, wherein we will be holding 75% stake.
Other
- Q1 is a softer quarter due to the nature of its business, a pattern seen for the last 15 years, and its Q4 is always the strongest quarter.
Show source
Before I start with the quarterly numbers, I would like to highlight that, as mentioned by Naresh Bhai and Abhishek Bhai in previous earnings calls, our Q1 is always a softer quarter due to the nature of business, and this has been the case for the last 15 years.
What the company said on its earnings call, taken from its own transcript. Not advice.
Questions and answers
Question
Krishan Parwani: Good evening, everyone, and thank you for joining us on Acutaas Chemicals Q1 FY '26 Earnings Conference Call. Today, we have with us Acutaas Chemicals management represented by Mr. Naresh Patel, Chairman and Managing Director; Mr. Abhishek Patel, Vice President, Strategy; and Mr. Bhavin Shah, Chief Financial Officer. I would now like to invite Mr. Bhavin Shah to initiate the proceedings. Over to you, sir. Thank you.
Answer, bhavin shah
Bhavin Shah: Thank you, Krishan. Good evening, everyone. We are pleased to welcome you all to our earnings conference call to discuss Q1 FY '26 financials. Please note that a copy of our disclosure is available on the Investors section of our website as well as on the stock exchanges. Please do note that anything said on this call, which reflects our outlook towards the future, or which could be construed as forward-looking statement, must be reviewed in conjunction with the risks that the company faces. The conference call is being recorded and the transcript, along with the audio of the same, will be made available on the website of the company and exchanges. Please also note that the audio of the conference call is the copyright material of Acutaas Chemicals and cannot be copied, rebroadcasted or attributed in press or media without specific and written consent of the company.
Answer, naresh patel
Naresh Patel: Thank you, Bhavin. Good evening, everyone. I hope you are all doing well. Let me begin by briefly touching on the key industries we operate in, and then I shall move to business updates. Starting with pharmaceutical, raw material prices have remained stable and demand for our products is steadily improving. The CDMO segment continues to attract strong interest. Battery chemicals – this segment is seeing significant momentum.
Answer, naresh patel
The U.S. has introduced the One Big Beautiful Bill Act replacing the IRA. While this Act removes subsidies on EVs, which could impact consumer demand, it retains and, in some areas, strengthens the manufacturing- related incentives. Page 2 of 16 Acutaas Chemicals Limited July 30, 2025 The Act restricts participation from a set of prohibited foreign entities and accelerates the sunset of manufacturing credits. This is driving urgency among manufacturers. And as a result, we are seeing a noticeable uptick in customer interest for our battery chemicals offering. Moving on to the semiconductor industry. We are seeing a similar dynamics.
Answer, naresh patel
Customer wants to diversify their supply chain and are looking for partners closer to their manufacturing basis. This brings me to a key development. We have entered into a joint venture in South Korea named Indichem, where we are investing approximately KRW30 billion. We will hold a 75% stake, while our Korean partner brings in technology and market access in exchange for a 25% stake. The facility will manufacture specialty chemicals used in chip production. We have strong visibility on both the product mix and customer base for this venture. While I can't share customer names but would like to highlight that we already have good visibility on who our customers will be and what kind of business we are expecting from this venture once the plant is up and running.
Answer, naresh patel
Now coming to our Q1 performance. Our revenue for Q1 FY '26 grew by 17.3% year-on-year to INR2,072 million. The growth came primarily from our advanced pharmaceutical intermediates business, while the specialty chemicals business was steady. Abhishek will walk you through the numbers in more detail shortly. Coming to the business updates, we successfully completed a virtual audit of our Unit II at Ankleshwar by Japan's PMDA. And I'm happy to share that it has been declared GMP compliant. That means both of our pharma intermediates facility are now PMDA GMP certified, something we are proud of as it reflects our strong focus on compliance and quality.
Answer, naresh patel
We also continue to strengthen our team, especially at the middle and senior levels, bringing in people with deep expertise to lead specific projects or business areas. This helps us operate more efficiently and allow the core leadership team to focus on long-term strategy. To conclude, we have good visibility in our pharma intermediates business as well as for the specialty chemicals business. Therefore, I'm confident we shall deliver 25% growth with stronger margin this year. With that, I shall now hand over to our Vice President, Strategy, Abhishek Patel, who will take you through the detailed business update. Over to you, Abhishek.
Answer, abhishek patel
Abhishek Patel: Thank you, Naresh bhai. Good evening, everyone. Let me provide further insight into our business performances. Starting with pharmaceutical intermediates. This segment delivered revenue of INR165.8 crores in Q1 FY '26, which is strong growth of 23.3% Y-o-Y, which was driven by core advanced pharmaceutical intermediates business as well as the CDMO segment. Moving on specialty chemicals business. This business segment reported flattish revenue of INR41.4 crores during the quarter.
Answer, abhishek patel
While the commodity chemicals business saw healthy growth Page 3 of 16 Acutaas Chemicals Limited July 30, 2025 driven by volumes and steady pricing, this was offset by softer performance of Baba Fine Chemicals business. On the capital expenditure side, capex for the quarter stood at INR69 crores, primarily allocated to Jhagadia site for electrolyte additive project. Let me give some further updates on the capex. Ankleshwar capex stands completed. Last pending block has been commercialized in the current quarter. Electrolyte additive capex at our site in Jhagadia is on track and expected to be completed by Q3 FY '26. Coming to solar, in addition to 10.8-megawatt plant, which was commissioned last quarter, I am delighted to share the successful commissioning of remaining 5-megawatt solar plant.
Answer, abhishek patel
Now we have in total 15.8-megawatt power plant, which will offset majority of our electricity cost at our Sachin, Ankleshwar and Jhagadia unit. Full benefit of this solar power plant will be visible from Q3 FY '26 onwards. Capex for pilot plant has already started at our Sachin unit. We hope to complete the same within a year time. Overall, the capex for the current year is expected to be around INR250 crores, and we have sufficient cash on hand to fund this capex. On the business update, starting with Pharmaceutical Intermediates segment, our remaining CDMO projects are progressing as per plan and are expected to begin contribution to the top line from Q4 FY '26 onwards. Moving on to semiconductor business.
Answer, abhishek patel
As Naresh Bhai mentioned, we are investing around KRW 30 billion in Korea in a joint venture named Indichem, wherein we will be holding 75% stake. Remaining 25% stake is given to our Korean partner for bringing product, technology and market access. To reiterate Naresh bhai's point, we have strong visibility on both the target customers and the product pipeline that we aim to manufacture under this venture. The capital expenditure plan and location of the plant have already been finalized, and we're now moving swiftly towards execution. We expect capex to be completed in second half of the calendar year 2026 with commercial production beginning by late 2026 or early 2027. On the customer front, we continue to build strong relationship in both Korea and Japan. While we have already, we are already well advanced in customer engagement in Korea, I am pleased to share that in Japan, we are in final stage of discussion with a large multinational customer.
Answer, abhishek patel
In our battery chemicals business, I'm happy to report that we have introduced a couple of new products with both existing and the new customers. Due to confidentiality agreements, we are unable to disclose the further details at this point of time. However, we expect these developments to translate into commercial contracts starting FY '27. Before I conclude, I want to reaffirm our confidence in delivering 25% revenue growth in FY '26. And on the margin front, we are again committed to drive the further improvements. Page 4 of 16 Acutaas Chemicals Limited July 30, 2025 With that, I will hand over floor to our CFO, Mr. Bhavin Shah, for the financial update. Over to you, Bhavin bhai.
Answer, bhavin shah
Bhavin Shah: Thank you, Abhishek bhai. I would like to briefly highlight the key performance metrics for the quarter before we open the floor for questions. Before I start with the quarterly numbers, I would like to highlight that, as mentioned by Naresh Bhai and Abhishek Bhai in previous earnings calls, our Q1 is always a softer quarter due to the nature of business, and this has been the case for the last 15 years. And therefore, the number might look suppressed on a sequential basis given our Q4 is always the strongest quarter. Having said this, let me start with the quarterly performance. Revenue from operations for the quarter reached INR207 crores, representing 17.3% growth Y-o-Y. Gross profit for the quarter was INR110.3 crores, reflecting 48.4% increase compared to the same period last year. The gross margin expanded by 1,117 basis points Y-o-Y to 53.2%.
Answer, bhavin shah
Gross margin was driven by cost optimization initiatives as well as improved product mix. EBITDA for the quarter was INR50.9 crores, which was up 72.4% Y-o-Y. EBITDA margins were at 24.6%, up 785 basis points Y-o-Y. EBITDA margin was driven by expansion in gross margin. PAT for the quarter was INR44 crores, which grew 3x compared to the PAT of INR14.7 crores in Q1 FY '25. PAT growth was driven by higher EBITDA margin and strong other income driven by foreign currency gains. PAT margin for the quarter was 21.2%, which show an expansion of 1,292 basis points Y-o-Y. Moving on to the balance sheet item. Net cash and cash equivalents were at INR270 crores. Our working capital for the quarter was around 128 days, which was increased by 14 days compared to Q4FY '25.
Answer, bhavin shah
This is mainly on account of the lower payable days due to the advanced payment for better pricing of raw materials, while for the full year, we believe our working capital would be around 110 days. Although there was an increase in working capital, I'm happy to share that we have generated a strong cash flow of INR94.6 crores from the operation during the quarter. With that, I request moderator to open the floor for questions. Thank you.
Answer, abhishek patel
Abhishek Patel: In electrolyte segment, we have proposed to manufacture electrolyte additives, which is an ingredient for electrolyte solution, which goes into the battery. For this, we have already done Page 5 of 16 Acutaas Chemicals Limited July 30, 2025 the market development. We have already signed contract in place with the customer. And then we are at the point of completing our capex with respect to this business. So once this capex has completed, the commercial full-fledged supply will start. And margin will again be a function of the scalability of that product in that plant. But we are hopeful that this business will give us a good margin as compared to other spec chem business of which we are operating into as of now.
Answer, abhishek patel
Abhishek Patel: In this business, I will not give you the exact number for the turnover. But what we can say is we are expecting 1.5x the asset turn in this business. We have announced the capital expenditure of INR177 crores for this business, which is for 2,000 metric ton of VC and 2,000 metric ton of FEC. Akhand: Okay. And the battery projects in India seem to be delayed if we look at Exide, Amara, Maruti and Tata Motors, almost everybody's battery projects are delayed. So, do you think that we can see any benefit of this investment in FY '27? Or will it be later?
Answer, abhishek patel
Abhishek Patel: Good question. See, let me just bring to you notice that, as I mentioned, we have already signed agreement in place for this business. And all our capacity, what is I just mentioned, this is for our export business. We are as of now not dependent for this capacity on the India. In future, whenever the India business gets going, we will supply with the additional capacity in place. So, we are not dependent on the domestic market. As and when the production plant gets completed, sorry, capex gets completed, we will start shipping our materials.
Answer, abhishek patel
Abhishek Patel: Sir, when we get into any business, we make sure that we should be competitive then only we launch any of our product.
Answer, abhishek patel
Abhishek Patel: In fact, I mentioned during my commentary also that this business growth is largely driven by our core advanced intermediate business. Of course, the CDMO business is important, but the large portion of this growth comes from the ex CDMO pharma intermediate business. Unfortunately, I will not be able to share the exact figures on this but let me again restate that it's a large portion of growth is driven by ex CDMO business growth. Page 6 of 16 Acutaas Chemicals Limited July 30, 2025 Nilesh Ghuge: Great.
Question
And is it volume driven or there is a change, I'm comparing Y-o-Y. So, is it because of this volume has gone up? Or is it price-driven growth?
Answer, abhishek patel
Abhishek Patel: Growth volumes are also there, but the realization has improved as compared to Q1 FY '25 because of favorable product mix.
Question
Nilesh Ghuge: Okay. Okay. And there is, I mean, if I look at the gross profit level, there is a significant jump in the gross profit level Q-on-Q and Y-o-Y also. But at the EBITDA level, sequentially, there is a dip. So, what cost has gone up? I mean, is it because of this operating cost or is it because of the product mix that your EBITDA margin is below, if I mean lower than the Q4, but at the gross profit, it's much, much better if I compare sequentially?
Answer, bhavin shah
Bhavin Shah: So, Nilesh, you have seen a better gross margin. And when we scale up, see, as I mentioned earlier, Q1 is always the lowest quarter. So, as we grow Q2, Q3, Q4 and our sales number will also grow there. So, margin will improve from here. So, this is where we are.
Answer, abhishek patel
Abhishek Patel: So, in nutshell, the gross margin improvement is there because of the, as I just mentioned, favorable product mix as well as the cost improvement measure which we saw in some of our largest products. And of course, as Bhavin bhai mentioned, the expense, the EBITDA margin level, the expense base expense level looks high as a percentage of sales because of the lower revenue base as compared to Q4 FY '25.
Answer, abhishek patel
Abhishek Patel: Yes. As I mentioned, we have a couple of new products added in this segment. And from that segment also, the customer developments are already being done and now we are at a good stage to get the revenue, but not in this financial year, it will start from next, early next financial year. And of course, there will be some additional capex would be required in terms of additional infrastructure utility as well as some additional capex, which will be around INR40 crores to INR50 crores in total. Abhijit: Okay. And are these electrolytes as well or there are some other categories of products?
Answer, abhishek patel
Abhishek Patel: No, Electrolyte additive specifically. Abhijit: You're right. Okay. Understood. Then just on Baba Fine Chemicals, as you mentioned in your opening remarks, the numbers have been a little bit soft. So, if you could please just help us understand what exactly is happening there? And how you see that semiconductor chemicals business overall trending over the next 2, 3 years?
Answer, abhishek patel
But as I mentioned earlier also that the purpose of this acquisition was to get into this semiconductor business, and that's the reason we are aggressively going into other market of Korea, Japan, Taiwan and where we see a good traction coming in. So, we are very hopeful that post acquisition of this business and the kind of market traction we are seeing in this market. And as I mentioned, we are very near to a Japanese customer in this segment. So hopefully, this business will again pick up and get us a better revenue in future along with other customers from Korea and Taiwan. Abhijit: Right. Just 2 last quick ones from me. I'll combine both of them.
Answer, abhishek patel
One is the gross margin has gone to 53% this quarter. And from your comments, it seems like these cost improvements that we have made are sustainable in nature. So, should we kind of expect gross margins to stay north of 50% in coming periods? That was question number one. And number 2, just on Darolutamide, I believe there has been a label expansion in the recent past. So, if you could please just share your thoughts on what this might mean in terms of implications for the growth, for our growth in that business? Also, anything you would be able to add on your new pharma CDMO projects that you're expecting by year-end?
Answer, abhishek patel
The location has been identified and finalized. So now it's a time for us to quickly move on to the execution of the capex. So that is expected to get completed by second half of calendar year 2026. And then by end of '26 or early 2027, we should be able to give the production.
Question
Krishan Parwani: Okay. That's great, sir. And just the last bit, given we are doing a lot of capex. So just wanted to know what is the split of the capex in FY '26 and FY '27, just from the, how much will you spend in '26 and '27?
Answer, abhishek patel
Abhishek Patel: So, capex number, those are similar to what we discussed earlier also. The electrolyte additives capex is INR180 crores; pilot plant is INR30 crores and maintenance capex is INR40 crores. And this includes some of the capex or infrastructure requirement in electrolyte additives segment for the new product also.
Answer, bhavin shah
Bhavin Shah: So segmental margin for Pharma is around 28% and specialty is around 11%.
Question
Jason Soans: Congrats on a very good set of numbers. Sir, just wanted to understand one thing. I mean, one is that you mentioned that there is a higher other income. And you also mentioned that there is a higher foreign exchange gain for you. So, is it possible to quantify that what is the gain number in this quarter?
Answer, bhavin shah
Bhavin Shah: So, in this quarter, we have other income of INR16 crores. So out of that, foreign exchange gain is around INR12.5 crores and interest income is INR3.5 crores.
Question
Jason Soans: And sir, just wanted to know, I mean, of course, the electrolyte additive capacity capex will actually get commissioned, let's say, by the end of this year, as you mentioned. So, we have 2,000 tons of VEC and FEC both. Just wanted to know -- you did mention that you are looking at an asset turn of 1.5x on the capex. Just wanted to know for '27, do we have a certain volume target in mind for this capex out of 2,000, 2,000 how much are we going to looking at a sales target or something like that?
Answer, abhishek patel
Abhishek Patel: I will not put any specific number to it. But just let me give you the update that we now have a full visibility on the capex we have planned for 2,000 metric ton of VC and 2,000 metric ton of FEC so it will ramp up very fast in FY '27. And in fact, now the next step will be for us to set up or find a new capacity to cater the demand traction what we see in the market.
Question
Jason Soans: Okay. Sure, sure. And sir, also wanted to know, I mean, you did speak about, of course, there's a good traction in the ex CDMO business. How is the pipeline looking, sir, going ahead for the core intermediates business also and any long-term contracts? How is the Fermion order scaling up? What, how is the visibility looking at going ahead for the API business?
Answer, abhishek patel
Abhishek Patel: For the ex CDMO business we have good visibility in terms of our product pipeline as we have very strong product pipeline, R&D pipeline up to patent expiry of API beyond 2040. So, for which we have already developed the intermediate, we have already sampled it. We already submitted to customer on a commercial scale. So that gives us the visibility and the confidence that our ex CDMO intermediate business will keep growing. And apart from that, we have a very good pipeline with the originator business also. This is over the year we have structured our business and going well over more than 15 years. On the Fermion side, this is largely Fermion business is a large portion comes from the CDMO space.
Answer, abhishek patel
And there, we have for that particular contract, we have long-term contract already been signed for the product which has got patent expiry beyond 2033 and most of the geography 2035, long- Page 10 of 16 Acutaas Chemicals Limited July 30, 2025 term supply contract is already in place. So that also gives us a good visibility. And apart from that, we have other CDMO business also coming in this financial year and next year as well.
Question
Jason Soans: Okay, sir. And just one last one from my side. Sir, I just wanted to know, of course, you are investing quite considerably in the semiconductors business. Now of course, this is towards building the semiconductor materials, which goes to the likes of TSMC, the big Samsung and of course, ultimately. But I just wanted to know like from a micro perspective, what, of course, this must be very, very critical and a very, very niche segment, a high value-add segment, probably there will be a lot of competition also. So just wanted to, if you can give us some color on how you are gearing up for this in terms of semiconductor, which can be a huge market for you. But just probably you are
Answer, naresh patel
Naresh Patel: So, I'm just adding that, Abhishek, we are incrementally apart from various product and which is already developed by Baba that we are expanding into this area. Okay. And this will start early 2027, that is the estimate right now, production and everything, as you mentioned earlier.
Question
Siddharth Purohit: What will be the key products in the CDMO that we will be targeting?
Answer, abhishek patel
Abhishek Patel: So actually, we have not, we have stopped giving any product level guidance on names. But as people already know about one of the CDMO project, which was publicly announced a year back. But then we have 3 more projects which are expected to get commercialized by end of this financial year and one of that, one of those new projects for one product, we have already supplied the validation quantity in Q4 FY '25.So now after regulatory approvals and all those things in place, it will start giving us the revenue by H2 FY '26. So those projects are on track as per our projection or as per our budget.
Question
Prashant Nair: Okay. Understood. And just one question on the Specialty Chemicals side. So how close are we or how much more time in terms of maybe quarters or say years will take to get to a steady-state margin profile there where say, peak margins in that business?
Answer, abhishek patel
Abhishek Patel: See, on a steady-state side, it's always a function of market dynamics. On steady-state side, I'm seeing the gross margin in the range of 48% to 50% around.
Show 3 more questions
Question
Prashant Nair: Okay. So, my question was on the Specialty Chemicals side. So where do you expect this business margins to stabilize? And how long could it take to get there?
Answer, abhishek patel
Abhishek Patel: Specialty business as of now, it is double digit at EBITDA level. And for that business, we are expecting in same kind of territory only. Once the electrolyte additive business picks up, it will have a better margin profile than the overall spec chem business.
Question
Kalpit Narvekar: Understood. And you're winning this business because you are more cost competitive from them versus them? Or is there some kind of move from China Plus One etcetera, that's helping the business win?
Answer, abhishek patel
Abhishek Patel: So Baba Fine Chem business side, we are expecting kind of similar revenue as compared to last year revenue. Akshay: Sir, what was the last year's revenue?
Answer, abhishek patel
These are not kind of those blockbuster products in the market, but they are, we see the revenue potential of INR50 crores to INR100 crores each for those products. Akshay: And after this commercialization, can we expect that our margins will improve from the FY '27 onwards?
Question
Lalit Kumar: Do you want to give your guidance for FY26 like you give for 25% or increase your improvement in this guidance?
Answer, abhishek patel
Abhishek Patel: No, no. We have already given the guidance of 25% during my commentary as well as in this commentary and we stick to this guidance.
Questions about this call
- When was the Acutaas Chemicals Q1 FY26 earnings call transcript filed?
- Acutaas Chemicals filed the transcript with the exchange on 5 Aug 2025. This page is built from that transcript.
- What does this page list?
- 55 statements from the transcript across 8 topics, 39 of them with a figure. Each statement is shown with the transcript sentence it came from.
- Are the analysts' questions included?
- Yes. 13 questions and management's answers are listed in the order they were asked, as the transcript prints them.
- Who wrote this page?
- DalalOS Data Desk. Assembled by software from the company's transcript. Not reviewed by a person. How it is made, and what it leaves out, is on the method page linked from the byline.